Laboratory diagnosis of anthrax

Thursday, 16 February, 2006

The Food and Drug Administration has reviewed Idaho Technology's 510(k) application and cleared the Joint Biological Agent Identification and Diagnostic System (JBAIDS) for use as an aid in the laboratory of diagnosis of anthrax. The JBAIDS Anthrax Detection System can detect the gene components of Bacillus anthracis in a variety of environmental sample types, and also clinical blood samples as well as cultured organisms.

The JBAIDS was selected by the US Department of Defense as the platform for use in rapid identification of over ten deadly pathogens associated with bioterrorism and diseases of military interest. The FDA clearance allows testing of blood and laboratory culture samples to aid in the laboratory identification of B anthracis, with results in less than one hour. The current method of growing, isolating and identifying a culture can take as long as several days for results.

Related News

Blood-based biomarker can detect sleep deprivation

The biomarker detected whether individuals had been awake for 24 hours with a 99.2% probability...

Epigenetic signature helps to diagnose rare breast tumour

The current way of diagnosing phyllodes tumours is to analyse their cellular features under a...

New instrument measures cardiovascular disease biomarkers

CVD-21 enables a 'liquid cardiovascular biopsy' for quantification of multiple...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd